Investor · 2 deals
New York, OS
Every published round Forepont Capital took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| GPN Vaccines | Series B | 7 Jun 2024 | $18m | Lead | ausceleratesa.org, Business News Australia, gpnvaccines.com | |
| Synchron | Series C | 16 Dec 2022 | $110m | Participant | Startup Daily (7 Nov 2025), Techboard, SmartCompany (16 Dec 2022), Startup Daily (16 Dec 2022), SmartCompany (16 Dec 2022) |
Companies Forepont Capital has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| GPN Vaccines | 7 Jun 2024, Series B | 1 | 1 | |
| Synchron | 16 Dec 2022, Series C | 1 | 0 |
Fund closes reported for Forepont Capital, as distinct from the investments it has made.
Companies Forepont Capital has backed that another company then bought. An exit for the holding, not a deal Forepont Capital did.
| Name | Role | Sources |
|---|---|---|
| Professor Ismail Kola | Partner | Business News Australia, gpnvaccines.com |
Stories naming Forepont Capital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GPN Vaccines, an Adelaide biotech, has closed a A$18 million Series B1 that beat its 15 million target, co-led by Forepont Capital and Mike Gregg, with Kern Capital joining as a new investor.